Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis Seite 1

27.01.2022 - The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health CanadaVANCOUVER, British Columbia, Jan. 27, 2022 (GLOBE NEWSWIRE) - KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) ... Seite 1

Related Keywords

United States ,Canada ,United Kingdom ,Vancouver ,British Columbia ,British ,Marvins Hausman ,Najla Guthrie ,Ketamineone Capital Limited Ketamine ,Nova Mentis Life Science Corp ,Science Inc ,European Union ,Health Canada ,Companies Plan ,Jointly Submit ,Psilocybin Clinical Trial Application ,One Capital Limited ,Nova Mentis Life Science ,Fragilex Syndrome ,Autism Spectrum Disorder ,